Clinical Research
An extensive variety of clinical research articles outlining the science of ketamine and ketamine treatment.
3 June 2018
Toward specific ways to combine ketamine and psychotherapy in treating depression
In major depression, remission rate in response to monoaminergic antidepressant is around 50%. The lack of strong synergies between classical antidepressants and psychotherapy may be due to the molecular effects of classical antidepressants. They modulate synapses but they do not substantially influence synaptogenesis. They also increase brain-derived neurotrophic factor (BDNF). However, for activity-dependent plasticity, BDNF …
Toward specific ways to combine ketamine and psychotherapy in treating depression Read More »
Learn more
24 May 2017
Ketamine Treatment and Global Brain Connectivity in Major Depression
Capitalizing on recent advances in resting-state functional connectivity magnetic resonance imaging (rs-fcMRI) and the distinctive paradigm of rapid mood normalization following ketamine treatment, the current study investigated intrinsic brain networks in major depressive disorder (MDD) during a depressive episode and following treatment with ketamine. Medication-free patients with MDD and healthy control subjects (HC) completed baseline …
Ketamine Treatment and Global Brain Connectivity in Major Depression Read More »
Learn more
24 November 2015
Efficacy of Ketamine in Bipolar Depression: Systematic
Results: Of the 721 articles that were screened, 5 studies that enrolled a total of 125 subjects with bipolar depression (mean age, 44.6±4.3 y and 65.6% females) were included in the systematic review; 3 randomized controlled trials (69 subjects) were included in the meta-analysis. The meta-analysis showed significant improvement in depression among patients receiving a …
Efficacy of Ketamine in Bipolar Depression: Systematic Read More »
Learn more
24 November 2013
Neuroplasticity and the next wave of antidepressant strategies
Depression is a common chronic psychiatric disorder that is also often co-morbid with numerous neurological and immune diseases. Accumulating evidence indicates that disturbances of neuroplasticity occur with depression, including reductions of hippocampal neurogenesis and cortical synaptogenesis. Improper trophic support stemming from stressor-induced reductions of growth factors, most notably brain derived neurotrophic factor (BDNF), likely drives …
Neuroplasticity and the next wave of antidepressant strategies Read More »
Learn more
